Jump Financial, LLC Savara Inc Transaction History

Jump Financial, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.19 - $5.59 $305,132 - $407,086	-72,824 Reduced 53.27%	63,876 $318,000
Q4 2023 Oct 21, 2024	BUY	$3.18 - $4.9 $331,273 - $510,452	104,174 Added 320.28%	136,700 $642,000
Q4 2023 Feb 07, 2024	BUY	$3.18 - $4.9 $331,273 - $510,452	104,174 Added 320.28%	136,700 $642,000
Q3 2023 Oct 21, 2024	BUY	$2.97 - $3.88 $96,602 - $126,200	32,526 New	32,526 $122,000
Q3 2023 Nov 07, 2023	BUY	$2.97 - $3.88 $96,602 - $126,200	32,526 New	32,526 $122,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.